Maijinjia Biotech Secures Tens of Millions in Series A Funding to Advance Blockmir-Based Oligonucleotide Therapeutics

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

It is reported that the funds from this round of financing will help advance relevant pipelines and expand the R&D team, further deepening and broadening the technological moat, and transforming MJJ Biotech into a more systematic and efficient Blockmir new drug development engine.

Guangdong Maijinjia Biotechnologies Co., Ltd. was established on August 14, 2019, founded by a team with over 20 years of experience in the fields of small molecule RNAs, modified oligonucleotides, patents, clinical trials, biotechnology, and business management. The company holds complete independent intellectual property rights to the Blockmir R&D technology platform. Jesper Wengel, a member of the Royal Danish Academy of Sciences and founder of Locked Nucleic Acid (LNA), serves as the chairman of the Academic Committee. Professor Hans Thorleif Møller, the Chief Scientific Officer, has been introduced to Huangpu through China's national talent recruitment program and is committed to advancing biopharmaceutical R&D in Guangzhou. Servier, an internationally renowned pharmaceutical company that was among the first to enter the Chinese market and has witnessed the entire process of China’s reform and opening-up, has signed a research and development cooperation agreement with the company. The aim is to jointly develop a new therapy for protein-related diseases in rare neurodegenerative conditions based on the Blockmir technology platform.

MJJ Biotech has developed the Blockmir nucleic acid drug research and development technology and the Dosevo nucleic acid drug screening technology. The company owns global rights to all related patents, rather than temporary or regional usage rights. Additionally, the company has applied for extensive patent protection for the Blockmir technology worldwide, with a broad patent portfolio in Europe, North America, China, and Japan. This portfolio covers the entire platform (327 miRNAs and all their mRNA targets), second-generation modification patterns, as well as several individual BlockmiRs targeting specific sites. It also includes a method for screening Blockmirs from large libraries with or without conjugates, forming a robust patent protection barrier.

MJJ Biotech, building on the 15-year research foundation of Academician Jesper Wengel's team, has established a highly efficient drug screening platform based on Blockmir technology, protected by a tight patent wall. Multiple animal studies have confirmed the efficacy of Blockmir technology; distribution tests of Blockmir in the mouse brain have been completed, verifying that Blockmir drugs can reach nearly all parts of the brain and enter various functional cells; it has been confirmed that Blockmir can upregulate protein expression (target for central nervous system diseases) in mice; partial confirmation of the half-life of Blockmir drugs has also been achieved.

In addition to the platform, MJJ BiotechR&D PipelineThere are eight categories, including cerebral cavernous malformations, acute respiratory distress syndrome, non-alcoholic fatty liver disease, Parkinson's disease, rare diseases of the central nervous system, aging, hepatitis C, and more. The Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, is collaborating with MJJ Biotech to develop a new therapy for protein-related diseases in rare neurodegenerative disorders based on the Blockmir technology platform. Cellular experiments are nearing completion, and animal studies are set to begin. The First Affiliated Hospital of Sun Yat-sen University is also working with MJJ Biotech on nucleic acid drug research targeting Acute Respiratory Distress Syndrome (ARDS), which has now entered the animal testing phase, with currently positive data outcomes. Additionally, the platform has established early research pipelines for liver and central nervous system diseases, identified targets for these pipelines, and found direct links between genes and diseases.

MJJ Biotech previously withFrench pharmaceutical company Servier reaches milestoneThe cooperation involves an upfront payment of nearly 2 million euros plus 35 million euros. Servier's feedback indicates that the patented technology can initially be developed into a drug. It has currently passed the mid-term go/no-go decision by Servier, and the meeting minutes show that Servier acknowledges MJJ Biotech's patented technology and intends to continue investing in research and development. Servier has provided its own equipment to MJJ Biotech’s Denmark laboratory as experimental apparatus and assigned technical personnel to assist on-site to accelerate the R&D process.

MJJ Biotech Co-founder,CEO Zhai JiajieWith the support of this round of financing, we will rapidly advance the relevant pipelines, submit an IND application in 2026, expand the R&D team, further broaden and deepen the technological moat, and build MJJ Biotech into a more systematic and efficient Blockmir new drug development engine.